Performance of BinaxNOW for Diagnosis of Malaria in a US Hospital
Performance of BinaxNOW for Diagnosis of Malaria in a US Hospital
复制标题
DOI：
10.1128/jcm.01013-12
复制
发表时间：
2012-09-01
影响因子：
9.4
通讯作者：
Banaei, Niaz
中科院分区：
文献类型：
--
作者：
DiMaio, Michael A.;Pereira, Irma T.;Banaei, Niaz
在非流行地区对疟原虫进行显微镜诊断和种属鉴定为疟疾诊断提供了一种可靠的方法，但在技术上具有挑战性。在美国进行了一项前瞻性研究，以测量BinaxNOW与显微镜（金标准）相比的性能。S.教学医院总体而言，BinaxNOW的敏感性为84.2%，特异性为99.8%。排除抗疟治疗的患者，敏感性为92.9%。重要的是，BinaxNOW最初将一个恶性疟原虫疟疾病例错误地归类为非恶性疟原虫。这些结果支持明智地使用BinaxNOW在非流行地区筛查疑似疟疾患者。
Microscopic diagnosis and species identification of Plasmodium in areas of nonendemicity provide a robust method for malaria diagnosis but are technically challenging. A prospective study was conducted to measure the performance of BinaxNOW compared to microscopy (the gold standard) in a U. S. teaching hospital. Overall, BinaxNOW was 84.2% sensitive and 99.8% specific. Excluding patients on antimalarial therapy, the sensitivity was 92.9%. Importantly, BinaxNOW initially misclassified a case of Plasmodium falciparum malaria as non-falciparum. These results support the judicious use of BinaxNOW in screening of individuals suspected of having malaria in areas of nonendemicity.